larotrectinib
Commercial- Indications
- TRK fusion cancers
Company intelligence / Profile preview
Loxo Oncology
Stamford, Connecticut, United Stateslilly.com ↗
- Ownership
- Private
- Development stage
- Commercial
01
Overview
Loxo Oncology developed targeted cancer therapies, with Vitrakvi (larotrectinib) receiving FDA approval. LOXO-292 (selpercatinib) showed impressive results with 68% of patients with RET fusion-positive non-small cell lung cancer experiencing tumor shrinkage, with plans for FDA filing by end of 2019[8].
- Therapeutic areas
- Oncology
- Modalities
- Small moleculestargeted therapies
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
Request access →03
Partnerships
Bayer (for Vitrakvi and LOXO-195)
Beyond the preview
Go deeper on Loxo Oncology.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Loxo Oncology.